Revance The (RVNC) - Stock Price & Dividends

Revance Therapeutics, Inc. is a biotechnology company that focuses on developing, manufacturing, and selling neuromodulators for both aesthetic and therapeutic purposes. They operate in the United States and globally. Their main product in development, DaxibotulinumtoxinA, has gone through phase III clinical trials targeting glabellar lines and cervical dystonia. It is currently undergoing phase II trials for upper facial lines, dynamic forehead lines, and lateral canthal lines. Additionally, the drug has completed phase II trials for adult upper limb spasticity and plantar fasciitis.

Besides their primary drug candidate, Revance Therapeutics, Inc. is working on OnabotulinumtoxinA, a biosimilar to BOTOX. They also provide Resilient Hyaluronic Acid (RHA) dermal filler for moderate to severe dynamic facial wrinkles, RHA Redensity for dynamic perioral rhytids, and OPUL Relational Commerce Platform, a financial technology tool. The company collaborates with Viatris Inc. for the production and commercialization of OnabotulinumtoxinA.

Established in 1999 as Essentia Biosystems, Inc., the company rebranded to Revance Therapeutics, Inc. in 2005. Headquartered in Nashville, Tennessee, the company's website is https://www.revance.com.